S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ALZN Alzamend Neuro Inc

0.726

-0.009 (-1.22%)

04 May 2024 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Alzamend Neuro Charts.

Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Alzamend Neuro Charts.

Alzamend Neuro Inc News

Form 8-K - Current report
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 3 February 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 6 January 2024 (4 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Saturday 16 December 2023 (5 months ago) • Edgar (US Regulatory)

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
Tuesday 12 December 2023 (5 months ago) • Business Wire

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
Tuesday 21 November 2023 (5 months ago) • Business Wire

Form 8-K - Current report
Friday 17 November 2023 (6 months ago) • Edgar (US Regulatory)

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Friday 17 November 2023 (6 months ago) • Business Wire

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
Tuesday 14 November 2023 (6 months ago) • Business Wire

Form 8-K - Current report
Tuesday 31 October 2023 (6 months ago) • Edgar (US Regulatory)

Alzamend Neuro Announces Reverse Stock Split
Monday 30 October 2023 (6 months ago) • Business Wire

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
Monday 23 October 2023 (6 months ago) • Business Wire

More Alzamend Neuro Inc News Articles

JP Morgan Chase

S&P ASX 300 Metals and M...

Invesco QQQ Trust Series 1

Gold vs US Dollar

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions